The country can’t ignore the fact that Asia is the future of medtech growth.
Don’t skimp on conducting due diligence.
How are you protecting your IP and keeping talent from going overseas?
Companies must be aware of the changing clinical trial regulatory environment for devices in China.
With differing cultural attitudes towards tissue donation and transplantation, be prepared for some complex hurdles.
Within this large and growing market, some companies are capitalizing, while others are faltering.
Entering the Japanese device market requires an excellent regulatory team.
You can never do enough due diligence.
Consider taking a multi-pronged approach to this complex landscape.
Choosing the right CRO has a big impact on product registration and time to market.